These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23121619)

  • 1. Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop.
    Van Etten RA; Mauro M; Radich JP; Goldman JM; Saglio G; Jamieson C; Soverini S; Gambacorti-Passerini C; Hehlmann R; Martinelli G; Perrotti D; Scadden DT; Skorski T; Tefferi A; Mughal TI
    Leuk Lymphoma; 2013 Jun; 54(6):1151-8. PubMed ID: 23121619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms.
    Mughal TI; Abdel-Wahab O; Rampal R; Mesa R; Koschmieder S; Levine R; Hehlmann R; Saglio G; Barbui T; Van Etten RA
    Leuk Lymphoma; 2016 Jul; 57(7):1517-26. PubMed ID: 27240645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.
    Mughal TI; Gotlib J; Mesa R; Koschmieder S; Khoury HJ; Cortes JE; Barbui T; Hehlmann R; Mauro M; Saussele S; Radich JP; Van Etten RA; Saglio G; Verstovek S; Gale RP; Abdel-Wahab O
    Leuk Res; 2018 Apr; 67():67-74. PubMed ID: 29466766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.
    Yung Y; Lee E; Chu HT; Yip PK; Gill H
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium.
    Abdel-Wahab O; Pardanani A; Bernard OA; Finazzi G; Crispino JD; Gisslinger H; Kralovics R; Odenike O; Bhalla K; Gupta V; Barosi G; Gotlib J; Guglielmelli P; Kiladjian JJ; Noel P; Cazzola M; Vannucchi AM; Hoffman R; Barbui T; Thiele J; Van Etten RA; Mughal T; Tefferi A
    Am J Hematol; 2012 May; 87(5):562-8. PubMed ID: 22460584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.
    Latremouille-Viau D; Guerin A; Gagnon-Sanschagrin P; Dea K; Cohen BG; Joseph GJ
    J Manag Care Spec Pharm; 2017 Feb; 23(2):214-224. PubMed ID: 28125373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies.
    Mughal TI; Pemmaraju N; Psaila B; Radich J; Bose P; Lion T; Kiladjian JJ; Rampal R; Jain T; Verstovsek S; Yacoub A; Cortes JE; Mesa R; Saglio G; van Etten RA
    Hematol Oncol; 2020 Dec; 38(5):654-664. PubMed ID: 32592408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions.
    Osman AEG; Deininger MW
    Blood Rev; 2021 Sep; 49():100825. PubMed ID: 33773846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?
    Carter BZ; Mak DH; Cortes J; Andreeff M
    Semin Hematol; 2010 Oct; 47(4):362-70. PubMed ID: 20875553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.
    Egan DN; Beppu L; Radich JP
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):184-9. PubMed ID: 25300870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current perspectives for the treatment of chronic myeloid leukemia.
    Aladağ E; Haznedaroğlu İC
    Turk J Med Sci; 2019 Feb; 49(1):1-10. PubMed ID: 30761815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukemia Stem Cells in Chronic Myeloid Leukemia.
    Shan Y; DeSouza N; Qiu Q; Li S
    Adv Exp Med Biol; 2019; 1143():191-215. PubMed ID: 31338821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of autophagy: a new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors.
    Calabretta B; Salomoni P
    Leuk Lymphoma; 2011 Feb; 52 Suppl 1(Suppl 1):54-9. PubMed ID: 21250825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2018 Mar; 93(3):442-459. PubMed ID: 29411417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic myeloid leukemia stem cells: targeting therapeutic implications.
    Mojtahedi H; Yazdanpanah N; Rezaei N
    Stem Cell Res Ther; 2021 Dec; 12(1):603. PubMed ID: 34922630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
    Herrmann O; Kuepper MK; Bütow M; Costa IG; Appelmann I; Beier F; Luedde T; Braunschweig T; Koschmieder S; Brümmendorf TH; Schemionek M
    BMC Cancer; 2019 Jul; 19(1):658. PubMed ID: 31272418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
    Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment and molecular monitoring update in chronic myeloid leukemia management.
    Sorel N; Cayssials É; Brizard F; Chomel JC
    Ann Biol Clin (Paris); 2017 Apr; 75(2):129-145. PubMed ID: 28377326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
    Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.